Literature DB >> 16759875

Suppression of galactosylceramidase (GALC) expression in the twitcher mouse model of globoid cell leukodystrophy (GLD) is caused by nonsense-mediated mRNA decay (NMD).

Wing C Lee1, Yuen K Tsoi, Chad A Dickey, Michael W Delucia, Dennis W Dickson, Christopher B Eckman.   

Abstract

The twitcher mouse is a pathologically and enzymatically authentic model of globoid cell leukodystrophy (GLD, Krabbe disease) that has been widely used for the evaluation of potential therapeutic approaches. This naturally occurring mouse model contains a premature stop codon (W339X) in the galactosylceramidase (GALC) gene that abolishes enzymatic activity. Using either immunocytochemical approaches or Western blot methodology, we have been unable to detect the truncated form of GALC expected to be produced in these animals. Nonsense-mediated mRNA decay (NMD) is a cellular protection mechanism that degrades newly synthesized transcripts containing a premature termination codon (PTC). Since the naturally occurring mutation in the twitcher mouse introduces a PTC, we hypothesized that NMD might affect the degradation of GALC mRNA in these animals. Consistent with this hypothesis, we determined that the amount of GALC transcript was inversely proportional to the number of twitcher containing alleles. Similar reductions in GALC mRNA were detected in a twitcher-derived Schwann cell line (TwS1) when compared to wild-type Schwann cells (IMS32). Anisomycin, emetine and puromycin, inhibitors of NMD, effectively increased the level of GALC transcript in the TwS1 cells providing further support for nonsense-mediated mRNA decay being the mechanism by which no GALC protein is detected in these animals. Understanding the mechanistic differences between the lack of enzymatic activity in the twitcher model and that observed with the missense mutations that cause human disease yields not only novel therapeutic insights but also highlights the need for additional animal models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759875     DOI: 10.1016/j.nbd.2006.03.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

1.  A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin.

Authors:  Chunmei Yang; Jinong Feng; Wenjia Song; Jicheng Wang; Becky Tsai; Yunwu Zhang; William A Scaringe; Kathleen A Hill; Paris Margaritis; Katherine A High; Steve S Sommer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-19       Impact factor: 11.205

Review 2.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease.

Authors:  Carla Andreia Teixeira; Catarina Oliveira Miranda; Vera Filipe Sousa; Telma Emanuela Santos; Ana Rita Malheiro; Melani Solomon; Gustavo H Maegawa; Pedro Brites; Mónica Mendes Sousa
Journal:  Neurobiol Dis       Date:  2014-03-06       Impact factor: 5.996

4.  Cell-autonomous expression of the acid hydrolase galactocerebrosidase.

Authors:  Christina R Mikulka; Joshua T Dearborn; Bruno A Benitez; Amy Strickland; Lin Liu; Jeffrey Milbrandt; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-06       Impact factor: 11.205

5.  Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.

Authors:  Gregory B Potter; Marta Santos; Muriel T Davisson; David H Rowitch; Dan L Marks; Ernesto R Bongarzone; Magdalena A Petryniak
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

6.  Insights into Krabbe disease from structures of galactocerebrosidase.

Authors:  Janet E Deane; Stephen C Graham; Nee Na Kim; Penelope E Stein; Rosamund McNair; M Begoña Cachón-González; Timothy M Cox; Randy J Read
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 7.  Experimental therapies in the murine model of globoid cell leukodystrophy.

Authors:  Yedda Li; Mark S Sands
Journal:  Pediatr Neurol       Date:  2014-08-08       Impact factor: 3.372

8.  Premature termination codons in PRPF31 cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay.

Authors:  Thomas Rio Frio; Nicholas M Wade; Adriana Ransijn; Eliot L Berson; Jacques S Beckmann; Carlo Rivolta
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.

Authors:  Daesung Shin; M Laura Feltri; Lawrence Wrabetz
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

Review 10.  New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones.

Authors:  Samantha J Spratley; Janet E Deane
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.